Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
IBUPROFEN
APOTEX INC
M01AE01
IBUPROFEN
200MG
CAPSULE
IBUPROFEN 200MG
ORAL
16/32/50/72/100/120/144/150/180/200/250/500
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883004; AHFS:
APPROVED
2011-11-21
Page 1 of 46 PRODUCT MONOGRAPH IBUPROFEN LIQUID GEL CAPSULES Ibuprofen Capsules 200 mg (free acid and potassium salt) EXTRA STRENGTH IBUPROFEN LIQUID GEL CAPSULES Ibuprofen Capsules 400 mg (free acid and potassium salt) Analgesic/Antipyretic APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 DATE OF REVISION: June 8, 2020 Submission Control No. 236867 Page 2 of 46 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ..............................................................................3 INDICATIONS AND CLINICAL USE ....................................................................................3 CONTRAINDICATIONS .........................................................................................................4 WARNINGS AND PRECAUTIONS ........................................................................................5 ADVERSE REACTIONS ........................................................................................................11 DRUG INTERACTIONS ........................................................................................................14 DOSAGE AND ADMINISTRATION ....................................................................................17 OVERDOSAGE ......................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ..................................................................19 STORAGE AND STABILITY ................................................................................................21 SPECIAL HANDLING INSTRUCTIONS .............................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................................21 PART II: SCIENTIFIC INFORMATION ...............................................................................23 PHARMACEUTICAL INFORMATION ................................... Կարդացեք ամբողջական փաստաթուղթը